Entering text into the input field will update the search result below

Takeda eosinophilic esophagitis asset resubmission accepted by FDA

Sep. 20, 2023 8:52 AM ETTakeda Pharmaceutical Company Limited (TAK) StockBy: Jonathan Block, SA News Editor
Eosinophilic esophagitis

Hailshadow/iStock via Getty Images

  • The US FDA has accepted resubmission of a New Drug Application for Takeda Pharmaceutical's (NYSE:TAK) eosinophilic esophagitis candidate TAK-721 (budesonide oral suspension).
  • The FDA action date is the first half of 2024.
  • In December 2021, Takeda (TAK) received a Complete Response Letter from the agency on the asset suggesting it conduct an additional trial.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About TAK

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Takeda Pharmaceutical Company Limited
Daiichi Sankyo Company, Limited
Bayer Aktiengesellschaft
Astellas Pharma Inc.
Merck KGaA
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.